4.5 Article

Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds

期刊

CELL CHEMICAL BIOLOGY
卷 23, 期 7, 页码 769-781

出版社

CELL PRESS
DOI: 10.1016/j.chembiol.2016.06.006

关键词

-

资金

  1. National Cancer Institute (NCI), NIH, under NCI Chemical Biology Consortium [HHSN261200800001E]
  2. NIH [GM114306-02, CA077337]
  3. American Cancer Society Research Scholar Grant [RSG-13-384-01-DMC]
  4. DoD Breast Cancer Research Program Award [W81XWH-14-1-0308]
  5. National Science Foundation Graduate Research Fellowship [DGE-1122492]
  6. Leslie H. Warner Postdoctoral Fellowship
  7. NIH predoctoral NRSA F31 fellowship [CA186676]
  8. Winship Cancer Institute of Emory University Cancer Center Support Grant [P30-CA138292]
  9. Arthur and Sarah Merrill Foundation

向作者/读者索取更多资源

The KDM5/JARID1 family of Fe(II)- and alpha-ketoglutarate-dependent demethylases removes methyl groups from methylated lysine 4 of histone H3. Accumulating evidence supports a role for KDM5 family members as oncogenic drivers. We compare the in vitro inhibitory properties and binding affinity of ten diverse compounds with all four family members, and present the crystal structures of the KDM5A-linked Jumonji domain in complex with eight of these inhibitors in the presence of Mn(II). All eight inhibitors structurally examined occupy the binding site of alpha-ketoglutarate, but differ in their specific binding interactions, including the number of ligands involved in metal coordination. We also observed inhibitor-induced conformational changes in KDM5A, particularly those residues involved in the binding of alpha-ketoglutarate, the anticipated peptide substrate, and intramolecular interactions. We discuss how particular chemical moieties contribute to inhibitor potency and suggest strategies that might be utilized in the successful design of selective and potent epigenetic inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据